Combined treatment of palmar hyperhidrosis with botulinum toxin type A and oxybutynin chloride: Results of a clinical, multicenter, prospective study

Campanati, Anna; Gregoriou, Stamatis; Consales, Veronica; Rizzetto, Giulio; Bobyr, Ivan; Diotallevi, Federico; Martina, Emanuela; Kontochristopoulos, George; Platsidaki, Eftychia; Offidani, Annamaria

doi:10.1111/dth.14039

Cited by 16 publications

(10 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Current research seems to indicate that the safety and efficacy profile of oxybutynin in hyperhidrosis allows the association with BoNT-A treatment. Specifically, we have recently examined the efficacy of sequential administration of oral oxybutynin chloride after BoNT-A injections vs. oral oxybutynin chloride in monotherapy in patients with primary palmar hyperhidrosis [39]. Moreover, we evaluated if the sequencing approach could allow the control of hyperhidrosis with lower dose of oral oxybutynin.…”

Section: Resultsmentioning

confidence: 99%

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

Martina

Diotallevi

Radi

et al. 2021

Toxins

Self Cite

View full text Add to dashboard Cite

Botulinum toxin is a superfamily of neurotoxins produced by the bacterium Clostridium Botulinum with well-established efficacy and safety profile in focal idiopathic hyperhidrosis. Recently, botulinum toxins have also been used in many other skin diseases, in off label regimen. The objective of this manuscript is to review and analyze the main therapeutic applications of botulinum toxins in skin diseases. A systematic review of the published data was conducted, following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Botulinum toxins present several label and off-label indications of interest for dermatologists. The best-reported evidence concerns focal idiopathic hyperhidrosis, Raynaud phenomenon, suppurative hidradenitis, Hailey–Hailey disease, epidermolysis bullosa simplex Weber–Cockayne type, Darier’s disease, pachyonychia congenita, aquagenic keratoderma, alopecia, psoriasis, notalgia paresthetica, facial erythema and flushing, and oily skin. Further clinical trials are still needed to better understand the real efficacy and safety of these applications and to standardize injection and doses protocols for off label applications.

show abstract

Section: Resultsmentioning

confidence: 99%

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

Martina

Diotallevi

Radi

et al. 2021

Toxins

Self Cite

View full text Add to dashboard Cite

show abstract

“…57 Sequencing treatment with injection of botulinum toxin followed by oral oxybutynin chloride administration was used in patients with primary focal palmar hyperhidrosis. 58 Combination therapy provided satisfactory clinical results and increased efficacy and safety compared with oral oxybutynin chloride monotherapy. In our systematic review, the combination of botulinum toxin with dermabrasion, 23 erbium:YAG laser, 23 oral tacrolimus, 59 and alitretinoin 34 was also found.…”

Section: Discussionmentioning

confidence: 96%

“…Previously published combination therapy for Hailey‐Hailey disease included doxycycline and vitamin PP, 56 narrowband ultraviolet‐B phototherapy and acitretin, 49 dermabrasion and Apremilast 57 . Sequencing treatment with injection of botulinum toxin followed by oral oxybutynin chloride administration was used in patients with primary focal palmar hyperhidrosis 58 . Combination therapy provided satisfactory clinical results and increased efficacy and safety compared with oral oxybutynin chloride monotherapy.…”

Section: Discussionmentioning

confidence: 99%

Botulinum toxin in treating Hailey‐Hailey disease: A systematic review

Zhang

Tang

Wang

et al. 2021

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Hailey-Hailey disease, also called benign familial chronic pemphigus, is a rare autosomal dominant disorder characterized by recurrent painful blistering, erosions, maceration in the intertriginous regions. 1,2 Hailey-Hailey disease is caused by mutations in the ATP2C1 gene located on chromosome 3q21-q24, whose function is to transport Ca 2+ /Mn 2+ into the Golgi apparatus and maintain normal intracellular concentrations of Ca 2+ /Mn 2+3 . The appearance of "dilapidated brick wall" was a characteristic histopathologic change of Hailey-Hailey disease. 4 Severe impairment of quality of life was observed in Hailey-Hailey disease in the aspects of symptoms, emotions, and social functioning. 5 Nowadays, treatment options for Hailey-Hailey disease include corticosteroids, antibiotics, botulinum toxin, CO 2 ablation laser, and dermabrasion. 6 CO 2 laser therapy as a long-term treatment option for Hailey-Hailey disease has been systematically reviewed, offering an effective and safe treatment option with minimal side effects. 7 Botulinum toxin has also been widely used in cosmetic dermatology, noncosmetic dermatology, and nondermatological indications. [8][9][10][11][12][13] As early as 2000, it was applied in a patient with Hailey-Hailey disease and provided a sustained

show abstract

“…It has also been shown to delay the initial need to urinate. Similarly, oxybutynin chloride can reduce the impact of acetylcholine on sweat glands and, in contrast to other anticholinergics, has a lower propensity for crossing the blood-brain barrier [1,8] .…”

Section: Mechanism Of Actionmentioning

confidence: 99%

An overview of oxybutynin and its use in primary hyperhidrosis

El-Samadony¹,

Hegab²,

Maghraby³

et al. 2023

Int. J. Dermatol. Venereology Leprosy Sci.

View full text Add to dashboard Cite

Primary hyperhidrosis typically starts in childhood and lasts until maturity. The main areas affected are the face, palms of the hands, soles of the feet, and the axilla. A patient with hyperhidrosis who started taking oxybutynin for urinary urgency is described in a case report from 1988; the patient's episodes of intense sweating stopped after a few hours. Numerous investigations conducted in recent years have confirmed its effectiveness in treating hyperhidrosis. Since it has recently been established that people with hyperhidrotic conditions have an overabundance of acetylcholine and 7-nicotinic receptors in their sympathetic ganglia, targeted treatment with oxybutynin has started to be reported. In 2003, the FDA approved oxybutynin transdermal administration for the first time in the form of a transdermal patch. The first transdermal delivery system (TDS) for oxybutynin was a patch that could be applied to the buttocks, hips, or abdomen. The transdermal patch was found to have less negative side effects and to be just as efficient in reducing the symptoms of overactive bladder when compared to oxybutynin taken orally. In the senior population, which is more likely to develop overactive bladder, transdermal distribution may also lessen the amount of pills required, memory loss, and drug-drug interactions, all of which are desired outcomes. Adults with hyperactive bladders may benefit from topically applied oxybutynin gel treatment. Oxybutynin chloride gel has been shown to be effective in treating primary focal hyperhidrosis in studies. Oxybutynin may have a longer half-life than other topical drugs like aluminium chloride, with a serum half-life of 62-84 hours following topical treatment. Patients' primary focal hyperhidrosis is treated less severely and have better health-related quality of life thanks to oxybutynin 3% gel.

show abstract

Combined treatment of palmar hyperhidrosis with botulinum toxin type A and oxybutynin chloride: Results of a clinical, multicenter, prospective study

Cited by 16 publications

References 34 publications

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review

Botulinum toxin in treating Hailey‐Hailey disease: A systematic review

An overview of oxybutynin and its use in primary hyperhidrosis

Contact Info

Product

Resources

About